Aedes albopictus

Exotic mosquitoes that are carriers (vectors) of dengue, yellow fever, Zika and chikungunya.

Antimicrobial resistance (AMR)

The ability of a microorganism (like bacteria, viruses and parasites) to stop an antimicrobial (such as antibiotics, antivirals and antimalarials) from working against it.

Blood Borne Viruses (BBV)

Viruses that are transmitted through contact between infected blood and uninfected blood (For example hepatitis B and hepatitis C).

Cervical cancer

A cancer of the cervix, often caused by human papillomavirus, which is a sexually transmissible infection.

Chronic disease

The term applied to a diverse group of diseases, such as heart disease, cancer and arthritis, that tend to be long-lasting and persistent in their symptoms or development. Although these features also apply to some communicable diseases (infections), the general term chronic diseases is usually confined to non-communicable diseases.

Closing the Gap

Council of Australian Governments’ Closing the Gap initiatives designed to close the gap in health equality between Indigenous and non-Indigenous Australians.

Communicable disease

An infectious disease transmissible (as from person to person) by direct contact with an affected individual or the individual’s discharges or by indirect means. Communicable (infectious) diseases include sexually transmitted diseases, vector-borne diseases, vaccine preventable diseases and antimicrobial resistant bacteria.

Council of Australian Governments (COAG)

COAG is the peak intergovernmental forum in Australia. The members of COAG are the Prime Minister, state and territory First Ministers and the President of the Australian Local Government Association.

Dengue

A mosquito-borne viral infection.

Diabetes

Refers to a group of syndromes caused by a malfunction in the production and release of insulin by the pancreas leading to a disturbance in blood glucose levels. Type 1 diabetes is characterised by the abrupt onset of symptoms, usually during childhood, and inadequate production of insulin requiring regular injections to regulate insulin levels. Type 2 diabetes is characterised by gradual onset commonly over the age of 45 years, but increasingly occurring in younger age groups, and is usually able to be regulated through dietary control.

Digital Health

Application of internet and other related technologies in the health care industry to improve the access, efficiency, effectiveness and quality of clinical and business processes utilised by health care organisations, practitioners, patients and consumers to improve the health status of patients.

Epidermolysis Bullosa

A rare inherited skin disorder that causes blistering and requires clinically appropriate dressings.

Financial year

The 12 month period from 1 July to 30 June.

General Practitioner (GP)

A medical practitioner who provides primary care to patients and their families within the community.

Genetically modified organisms

Organisms modified by gene technology.

Gene technology

Gene technology is a technique for the modification of genes or other genetic material.

Haemopoietic progenitor cell (HPC)

Blood cells found in bone marrow, peripheral blood and umbilical cord blood that are capable of self-renewal into all blood cell types.

Health care

Services provided to individuals or communities to promote, maintain, monitor or restore health. Health care is not limited to medical care and includes self-care.

Health outcome

A change in the health of an individual or population due wholly or partly to a preventive or clinical intervention.

Hepatitis B (serum hepatitis)

An acute (sometimes fatal) form of viral hepatitis transmitted by sexual contact, by transfusion or by ingestion of contaminated blood or other bodily fluids.

Hepatitis C

A blood borne viral disease that can result in serious liver disease such as cirrhosis, liver failure and liver cancer. Hepatitis C is usually transmitted by parenteral means (as injection of an illicit drug or blood transfusion or exposure to blood or blood products).

Human papillomavirus (HPV)

A virus that causes genital warts and which is linked in some cases to the development of more serious cervical cell abnormalities.

Illicit drugs

The term ‘illicit drug’ can encompass a number of broad concepts including:

• illegal drugs – a drug that is prohibited from manufacture, sale or possession in Australia – for example, cannabis, cocaine, heroin and ecstasy;
• misuse of pharmaceuticals (drugs that are available from a pharmacy, over-the-counter or by prescription), which may be subject to misuse – for example, opioid-based pain relief medications, opioid substitution therapies, benzodiazepines, over-the-counter codeine and steroids; and
• other psychoactive substances – legal or illegal, potentially used in a harmful way – for example, kava, or inhalants such as petrol, paint or glue.

Immunisation

Inducing immunity against infection by the use of an antigen to stimulate the body to produce its own antibodies. See vaccination.

Incidence

The number of new cases (of an illness or event, and so on) occurring during a given period. Compare with prevalence.

Jurisdictions

In the Commonwealth of Australia, these include the six states, the Commonwealth Government and the two territories.

Measles

A highly contagious infection, usually of children, that causes flu-like symptoms, fever, a typical rash and sometimes serious secondary problems such as brain damage. Preventable by vaccine.

Medical indemnity insurance

A form of professional indemnity cover that provides surety to medical practitioners and their patients in the event of an adverse outcome arising from medical negligence.

Medical Services Advisory Committee (MSAC)

MSAC is an independent non-statutory committee established by the Australian Government.

MSAC appraises new medical services proposed for public funding, and provides advice to Government on whether a new medical service should be publicly funded (and if so, its circumstances) on an assessment of its comparative safety, clinical effectiveness, cost-effectiveness, and total cost, using the best available evidence.

Medicare

A national, Government-funded scheme that subsidises the cost of personal medical services for all Australians and aims to help them afford medical care. The Medicare Benefits Schedule (MBS) is the listing of the Medicare services subsidised by the Australian Government. The schedule is part of the wider MBS (Medicare).

Memorandum of Understanding

A written but non-contractual agreement between two or more entities or other parties to take a certain course of action.

Meningococcal disease

The inflammation of meninges of the brain and the spinal cord caused by meningococcal bacteria that invade the body through the respiratory tract. The infection develops quickly and is often characterised by fever, vomiting, an intense headache, stiff neck and septicemia (an infection in the bloodstream).

Oncology

The study, knowledge and treatment of cancer and tumours.

Organisation for Economic Co-operation and Development (OECD)

An organisation of 35 countries (mostly developed and some emerging, such as Mexico, Chile and Turkey), including Australia. The OECD’s aim is to promote policies that will improve the economic and social wellbeing of people around the world.

Outcomes

Outcomes are the Government’s intended results, benefits or consequences for the Australian community. The Government requires entities, such as the Department, to use outcomes as a basis for budgeting, measuring performance and reporting. Annual administered funding is appropriated on an outcomes basis. The Department’s current outcomes are listed on page 17.

Out-of-pocket costs

The total costs incurred by individuals for health care services over and above any refunds from Medicare and private health insurance funds.

Palliative care

Care provided to achieve the best possible quality of life for patients with a progressive and far-advanced disease, with little or no prospect of cure.

Pathology

The study and diagnosis of disease through the examination of organs, tissues, cells and bodily fluids.

Pharmaceutical Benefits Advisory Committee (PBAC)

PBAC is an independent expert body appointed by the Australian Government. Members include doctors, health professionals, health economists and consumer representatives.

Its primary role is to recommend new medicines for listing on the PBS. No new medicine can be listed unless the committee makes a positive recommendation.

Pharmaceutical Benefits Scheme (PBS)

A national, Government-funded scheme that subsidises the cost of a wide range of pharmaceutical drugs for all Australians to help them afford standard medications. The PBS lists all the medicinal products available under the PBS and explains the uses for which they can be subsidised.

Portfolio Budget Statements

Statements prepared by portfolios to explain the Budget appropriations in terms of outcomes and programs.

Prevalence

The number or proportion (of cases, instances, and so forth) in a population at a given time. In relation to cancer, prevalence refers to the number of people alive who had been diagnosed with cancer in a prescribed period (usually 1, 5, 10 or 26 years). Compare with incidence.

Primary care

Provides the patient with a broad spectrum of care, both preventive and curative, over a period of time and coordinates all of the care the person receives.

Program/Programme

A specific strategy, initiative or grouping of activities directed toward the achievement of Government policy or a common strategic objective.

Prostheses List

Under the Private Health Insurance Act 2007, private health insurers are required to pay benefits for a range of prostheses that are provided as part of an episode of hospital treatment or hospital substitute treatment for which a patient has cover and for which a Medicare benefit is payable for the associated professional service. The types of products on the Prostheses List include cardiac pacemakers and defibrillators, cardiac stents, joint replacements and intraocular lenses, as well as human tissues such as human heart valves. The list does not include external legs, external breast prostheses, wigs and other such devices. The Prostheses List contains prostheses and human tissue prostheses and the benefit to be paid by the private health insurers. The Prostheses List is published bi-annually.

Public health

Activities aimed at benefiting a population, with an emphasis on prevention, protection and health promotion as distinct from treatment tailored to individuals with symptoms. Examples include anti-smoking education campaigns and screening for diseases such as cancer of the breast or cervix.

Quality Use of Medicines (QUM)

QUM means:

• selecting management options wisely;
• choosing suitable medicines if a medicine is considered necessary; and
• using medicines safely and effectively.

The definition of QUM applies equally to decisions about medicine use by individuals and decisions that affect the health of the population.

The definition of QUM applies equally to decisions about medicine use by individuals and decisions that affect the health of the population.

Radiation oncology (radiotherapy)

The study and discipline of treating malignant disease with radiation. The treatment is referred to as radiotherapy or radiation therapy.

Registrar

Any person undertaking medical vocational training in a recognised medical specialty training program accredited by the Australian Medical Council.

Sexually transmissible infection (STI)

An infectious disease that can be passed to another person by sexual contact. Notable examples include chlamydia and gonorrhoea.

Stoma

Artificial body opening in the abdominal region, for the purpose of waste removal.

Vaccination

The process of administering a vaccine to a person to produce immunity against infection. See immunisation.

World Health Organization (WHO)

The WHO is a specialised agency of the United Nations (UN). Its primary role is to direct and coordinate international health within the UN system. The WHO has 194 Member States, including Australia.

17AI

Letter of transmittal

A copy of the letter of transmittal signed and dated by accountable authority on date final text approved, with statement that the report has been prepared in accordance with section 46 of the Act and any enabling legislation that specifies additional requirements in relation to the annual report.

Mandatory

17AJ(a)

Table of contents.

Mandatory

17AJ(b)

Alphabetical index.

Mandatory

17AJ(c)

Glossary

Glossary of abbreviations and acronyms.

Mandatory

17AJ(d)

List of requirements

List of requirements.

Mandatory

17AJ(e)

Contact details

Details of contact officer.

Mandatory

17AJ(f)

Contact details

Entity’s website address.

Mandatory

17AJ(g)

Contact details

Electronic address of report.

Mandatory

17AD(a)

Secretary's Review

A review by the accountable authority of the entity.

Mandatory

17AE(1)(a)(i)

Part 1.1: Department Overview

A description of the role and functions of the entity.

Mandatory

17AE(1)(a)(ii)

Part 1.3: Structure Chart

A description of the organisational structure of the entity.

Mandatory

17AE(1)(a)(iii)

Part 1.2: Department-Specific Outcomes

A description of the outcomes and programmes administered by the entity.

Mandatory

17AE(1)(a)(iv)

Part 1.1: Department Overview

A description of the purposes of the entity as included in corporate plan.

Mandatory

17AE(1)(b)

Part 1.3: Structure Chart

An outline of the structure of the portfolio of the entity.

Portfolio departments ‑ mandatory

17AE(2)

N/A

Where the outcomes and programs administered by the entity differ from any Portfolio Budget Statement, Portfolio Additional Estimates Statement or other portfolio estimates statement that was prepared for the entity for the period, include details of variation and reasons for change.

If applicable, Mandatory

17AD(c)(i); 16F

Part 2.1: 2017-18 Annual Performance Statements

Annual performance statement in accordance with paragraph 39(1)(b) of the Act and section 16F of the Rule.

Mandatory

17AF(1)(a)

Part 4.1: Financial Statements Performance and Process

A discussion and analysis of the entity’s financial performance.

Mandatory

17AF(1)(b)

Part 2.2: Entity Resource Statements

A table summarising the total resources and total payments of the entity.

Mandatory

17AF(2)

N/A

If there may be significant changes in the financial results during or after the previous or current reporting period, information on those changes, including: the cause of any operating loss of the entity; how the entity has responded to the loss and the actions that have been taken in relation to the loss; and any matter or circumstances that it can reasonably be anticipated will have a significant impact on the entity’s future operation or financial results.

If applicable, Mandatory.

17AG(2)(a)

Certification of departmental fraud control arrangements

Information on compliance with section 10 (fraud systems)

Mandatory

17AG(2)(b)(i)

Certification of departmental fraud control arrangements

A certification by accountable authority that fraud risk assessments and fraud control plans have been prepared.

Mandatory

17AG(2)(b)(ii)

Certification of departmental fraud control arrangements

A certification by accountable authority that appropriate mechanisms for preventing, detecting incidents of, investigating or otherwise dealing with, and recording or reporting fraud that meet the specific needs of the entity are in place.

Mandatory

17AG(2)(b)(iii)

Certification of departmental fraud control arrangements

A certification by accountable authority that all reasonable measures have been taken to deal appropriately with fraud relating to the entity.

Mandatory

17AG(2)(c)

Part 3.1: Corporate Governance

An outline of structures and processes in place for the entity to implement principles and objectives of corporate governance.

Mandatory

17AG(2)(d) – (e)

N/A

A statement of significant issues reported to Minister under paragraph 19(1)(e) of the Act that relates to non‑compliance with Finance law and action taken to remedy non‑compliance.

If applicable, Mandatory

17AG(3)

Part 3.4: External Scrutiny and Compliance

Information on the most significant developments in external scrutiny and the entity’s response to the scrutiny.

Mandatory

17AG(3)(a)

Judicial decisions and decisions of administrative tribunals

Information on judicial decisions and decisions of administrative tribunals and by the Australian Information Commissioner that may have a significant effect on the operations of the entity.

If applicable, Mandatory

17AG(3)(b)

Part 3.4: External Scrutiny and Compliance

Information on any reports on operations of the entity by the Auditor‑General (other than report under section 43 of the Act), a Parliamentary Committee, or the Commonwealth Ombudsman.

If applicable, Mandatory

17AG(3)(c)

N/A

Information on any capability reviews on the entity that were released during the period.

If applicable, Mandatory

17AG(4)(a)

Part 3.2: People

An assessment of the entity’s effectiveness in managing and developing employees to achieve entity objectives.

Mandatory

17AG(4)(b)

Appendix 1: Workforce Statistics

Statistics on the entity’s APS employees on an ongoing and non‑ongoing basis; including the following: Statistics on staffing classification level, Statistics on full‑time employees, Statistics on part‑time employees, Statistics on gender, Statistics on staff location, Statistics on employees who identify as Indigenous.

Mandatory

17AG(4)(c)

Information on any enterprise agreements, individual flexibility arrangements, Australian workplace agreements, common law contracts and determinations under subsection 24(1) of the Public Service Act 1999.

Mandatory

17AG(4)(c)(i)

Table 2: Staff numbers by classification at 30 June 2018

Information on the number of SES and non‑SES employees covered by agreements etc identified in paragraph 17AG(4)(c).

Mandatory

17AG(4)(c)(ii)

Salary Ranges by Classification level

The salary ranges available for APS employees by classification level.

Mandatory

17AG(4)(c)(iii)

Table 9: Non-salary benefits

A description of non‑salary benefits provided to employees.

Mandatory

17AG(4)(d)(i)

APS performance pay

Information on the number of employees at each classification level who received performance pay.

If applicable, Mandatory

17AG(4)(d)(ii)

N/A

Information on aggregate amounts of performance pay at each classification level.

If applicable, Mandatory

17AG(4)(d)(iii)

N/A

Information on the average amount of performance payment, and range of such payments, at each classification level.

If applicable, Mandatory

17AG(4)(d)(iv)

N/A

Information on aggregate amount of performance payments.

If applicable, Mandatory

17AG(5)

Assessment of asset management effectiveness

An assessment of effectiveness of assets management where asset management is a significant part of the entity’s activities.

If applicable, mandatory

17AG(6)

Performance assessment against Commonwealth Procurement Rules

An assessment of entity performance against the Commonwealth Procurement Rules.

Mandatory

17AG(7)(a)

Consultancy summary statement

A summary statement detailing the number of new contracts engaging consultants entered into during the period; the total actual expenditure on all new consultancy contracts entered into during the period (inclusive of GST); the number of ongoing consultancy contracts that were entered into during a previous reporting period; and the total actual expenditure in the reporting year on the ongoing consultancy contracts (inclusive of GST).

Mandatory

17AG(7)(b)

Consultancy contracts summary

A statement that “During [reporting period], [specified number] new consultancy contracts were entered into involving total actual expenditure of $[specified million]. In addition, [specified number] ongoing consultancy contracts were active during the period, involving total actual expenditure of $[specified million]”.

Mandatory

17AG(7)(c)

Part 3.3: Financial and Property Management

A summary of the policies and procedures for selecting and engaging consultants and the main categories of purposes for which consultants were selected and engaged.

Mandatory

17AG(7)(d)

Part 3.3: Financial and Property Management

A statement that “Annual reports contain information about actual expenditure on contracts for consultancies. Information on the value of contracts and consultancies is available on the AusTender website.”

Mandatory

17AG(8)

Part 3.3: Financial and Property Management

If an entity entered into a contract with a value of more than $100 000 (inclusive of GST) and the contract did not provide the Auditor‑General with access to the contractor’s premises, the report must include the name of the contractor, purpose and value of the contract, and the reason why a clause allowing access was not included in the contract.

If applicable, Mandatory

17AG(9)

Part 3.3: Financial and Property Management

If an entity entered into a contract or there is a standing offer with a value greater than $10 000 (inclusive of GST) which has been exempted from being published in AusTender because it would disclose exempt matters under the FOI Act, the annual report must include a statement that the contract or standing offer has been exempted, and the value of the contract or standing offer, to the extent that doing so does not disclose the exempt matters.

If applicable, Mandatory

17AG(10)(a)

Part 3.3: Financial and Property Management

A statement that “[Name of entity] supports small business participation in the Commonwealth Government procurement market. Small and Medium Enterprises (SME) and Small Enterprise participation statistics are available on the Department of Finance’s website.”

Mandatory

17AG(10)(b)

Part 3.3: Financial and Property Management

An outline of the ways in which the procurement practices of the entity support small and medium enterprises.

Mandatory

17AG(10)(c)

Part 3.3: Financial and Property Management

If the entity is considered by the Department administered by the Finance Minister as material in nature—a statement that “[Name of entity] recognises the importance of ensuring that small businesses are paid on time. The results of the Survey of Australian Government Payments to Small Business are available on the Treasury’s website.”

If applicable, Mandatory

17AD(e)

Part 4.2: 2017-18 Financial Statements

Inclusion of the annual financial statements in accordance with subsection 43(4) of the Act.

Mandatory

17AH(1)(a)(i)

Advertising and market research

If the entity conducted advertising campaigns, a statement that “During [reporting period], the [name of entity] conducted the following advertising campaigns: [name of advertising campaigns undertaken]. Further information on those advertising campaigns is available at [address of entity’s website] and in the reports on Australian Government advertising prepared by the Department of Finance. Those reports are available on the Department of Finance’s website.”

If applicable, Mandatory

17AH(1)(a)(ii)

N/A

If the entity did not conduct advertising campaigns, a statement to that effect.

If applicable, Mandatory

17AH(1)(b)

Grants

A statement that “Information on grants awarded by [name of entity] during [reporting period] is available at [address of entity’s website].”

If applicable, Mandatory

17AH(1)(c)

Disability reporting

Outline of mechanisms of disability reporting, including reference to website for further information.

Mandatory

17AH(1)(d)

Freedom of information

Website reference to where the entity’s Information Publication Scheme statement pursuant to Part II of FOI Act can be found.

Mandatory

17AH(1)(e)

N/A

Correction of material errors in previous annual report

If applicable, mandatory

17AH(2)

Part 3.4: External Scrutiny and Compliance

Information required by other legislation

Mandatory